

Author: Dudek Dariusz Rakowski Tomasz Bartus Stanislaw Giszterowicz Dawid Dobrowolski Wojciech Zmudka Krzysztof Zalewski Jaroslaw Ochala Andrzej Wieja Pawel Janus Bogdan Dziewierz Artur Legutko Jacek Bryniarski Leszek Dubiel Jacek
Publisher: Springer Publishing Company
ISSN: 0929-5305
Source: Journal of Thrombosis and Thrombolysis, Vol.30, Iss.3, 2010-10, pp. : 347-353
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated the role of early abciximab administration on top of early clopidogrel 600 mg loading dose in patients with STEMI treated with PPCI. A total of 73 non-shock STEMI < 6 h patients admitted to remote hospitals with anticipated delay to PPCI < 90 min were randomly assigned to three study groups—24 pts received abciximab before transfer to cathlab (early = group EA), 27 in cathlab during PPCI (late = group LA) and in 22 abciximab administration was left to operator’s discretion during PPCI (selective = SA; given in 22.7% of patients). All patients received clopidogrel (600 mg), aspirin and heparin (70 U/kg) before transfer to cathlab. Angiography revealed more frequent infarct-related artery patency (TIMI 2 + 3: EA vs LA vs SA: 45.8 vs 18.5 vs 13.6%,
Related content








JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 6, 2015-06 ,pp. :


JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 11, 2015-11 ,pp. :